Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Ultragenyx published its 2025 Impact Report, outlining ESG progress across innovation, patient access, and governance. The company invested 62% of operating expenses in R&D across 160+ clinical trial sites in 19 countries while supporting over 700 patients globally through access programs. The report notes $3.3 million in charitable contributions and medical education grants during 2025, alongside strong employee engagement metrics with an 86% engagement score.
Key figures
- Rd expense pct
- 62%
- Volunteer hours
- 2,800+
- Charitable donations
- $3.3 million
- Clinical trial sites
- 160+
- Employee engagement score
- 86%
- Renewable electricity pct
- ~100%
- Patients supported access programs
- 700+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.